Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases

Donato Callegaro-Filho, John J. Kavanagh, Alpa M. Nick, Pedro T. Ramirez, Kathleen M. Schmeler

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. Case Description: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. Conclusion: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance.

Original languageEnglish (US)
Pages (from-to)97-101
Number of pages5
JournalCase Reports in Oncology
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Topotecan
Uterine Cervical Neoplasms
Neoplasm Metastasis
Therapeutics
Epidermal Growth Factor Receptor
Cisplatin
Radiotherapy
Lymph Nodes
Erlotinib Hydrochloride
Cervix Uteri
Squamous Cell Carcinoma
Radiation
Recurrence

Keywords

  • Epidermal growth factor receptor inhibitor
  • Erlotinib
  • Maintenance therapy
  • Recurrent cervical cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases. / Callegaro-Filho, Donato; Kavanagh, John J.; Nick, Alpa M.; Ramirez, Pedro T.; Schmeler, Kathleen M.

In: Case Reports in Oncology, Vol. 7, No. 1, 01.01.2014, p. 97-101.

Research output: Contribution to journalArticle

@article{842ff12ae0314857b34e27ceb88ed781,
title = "Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases",
abstract = "Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. Case Description: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. Conclusion: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance.",
keywords = "Epidermal growth factor receptor inhibitor, Erlotinib, Maintenance therapy, Recurrent cervical cancer",
author = "Donato Callegaro-Filho and Kavanagh, {John J.} and Nick, {Alpa M.} and Ramirez, {Pedro T.} and Schmeler, {Kathleen M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1159/000358916",
language = "English (US)",
volume = "7",
pages = "97--101",
journal = "Case Reports in Oncology",
issn = "1662-6575",
number = "1",

}

TY - JOUR

T1 - Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases

AU - Callegaro-Filho, Donato

AU - Kavanagh, John J.

AU - Nick, Alpa M.

AU - Ramirez, Pedro T.

AU - Schmeler, Kathleen M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. Case Description: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. Conclusion: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance.

AB - Introduction: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this setting. Case Description: A 53-year-old woman with stage IB2 squamous cell carcinoma of the cervix was initially treated with chemoradiation. Six months after completing treatment, she developed a recurrence in the common iliac and para-aortic lymph nodes above the previous radiation field and was treated with additional radiation therapy. Two years later, she developed recurrent disease in the left supraclavicular lymph nodes and was treated with chemoradiation followed by 3 cycles of adjuvant cisplatin and topotecan. She had a complete response and was placed on maintenance therapy with topotecan and erlotinib, which was well tolerated and produced minimal side effects. After 20 months of maintenance therapy, it was discontinued given the long interval without evidence of disease. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment. Conclusion: We noted a sustained response in a patient with recurrent metastatic cervical cancer treated with radiotherapy, cisplatin, and topotecan followed by maintenance therapy with topotecan and erlotinib. Further evaluation of the role of EGFR inhibitors in this setting should be considered given their favorable toxicity profile and biological relevance.

KW - Epidermal growth factor receptor inhibitor

KW - Erlotinib

KW - Maintenance therapy

KW - Recurrent cervical cancer

UR - http://www.scopus.com/inward/record.url?scp=84900496801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900496801&partnerID=8YFLogxK

U2 - 10.1159/000358916

DO - 10.1159/000358916

M3 - Article

AN - SCOPUS:84900496801

VL - 7

SP - 97

EP - 101

JO - Case Reports in Oncology

JF - Case Reports in Oncology

SN - 1662-6575

IS - 1

ER -